Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(18 sites)

United States

USC Norris Comprehensive Cancer Center, Los Angeles, California

University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Stanford Health Care - Skin Cancer Program, Stanford, California

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado

Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida